{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:16:45Z","timestamp":1788844605676,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004507","name":"Central Drug Research Institute","doi-asserted-by":"publisher","award":["11123"],"award-info":[{"award-number":["11123"]}],"id":[{"id":"10.13039\/501100004507","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jchromb.2026.124975","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:37:50Z","timestamp":1771605470000},"page":"124975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Pharmacokinetic, tissue distribution, permeability, protein binding and stability studies of finerenone in SD rats using validated UPLC and LC-MS method"],"prefix":"10.1016","volume":"1274","author":[{"given":"Shivam","family":"Rathaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parag","family":"Varshney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debalina","family":"Maity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaur R.","family":"Gayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1172","key":"10.1016\/j.jchromb.2026.124975_bb0005","volume":"15","author":"Rohde","year":"2021","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"9","key":"10.1016\/j.jchromb.2026.124975_bb0010","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jchromb.2026.124975_bb0015","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s13318-018-0483-9","article-title":"Pharmacokinetics of the novel, selective, non-steroidal mineralocorticoid receptor antagonist Finerenone in healthy volunteers: results from an absolute bioavailability study and drug-drug interaction studies in vitro and in vivo","volume":"43","author":"Heinig","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.jchromb.2026.124975_bb0020","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/fcp.12170","article-title":"Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies","volume":"30","author":"Lentini","year":"2016","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.jchromb.2026.124975_bb0025","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/17512433.2022.2094770","article-title":"Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes","volume":"15","author":"Lerma","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"27","key":"10.1016\/j.jchromb.2026.124975_bb0030","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.jchromb.2026.124975_bb0035","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cpdd.263","article-title":"Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment","volume":"5","author":"Heinig","year":"2016","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"5","key":"10.1016\/j.jchromb.2026.124975_bb0040","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s13318-019-00547-x","article-title":"Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with mild or moderate hepatic impairment","volume":"44","author":"Heinig","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.jchromb.2026.124975_bb0045","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.jchromb.2026.124975_bb0050","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"Barfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jchromb.2026.124975_bb0055","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2147\/TCRM.S325916","article-title":"Role of finerenone in the treatment of diabetic kidney disease: patient selection and clinical perspectives","volume":"18","author":"Shaikh","year":"2022","journal-title":"Ther. Clin. Risk Manag."},{"issue":"4","key":"10.1016\/j.jchromb.2026.124975_bb0060","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000506275","article-title":"Finerenone reduces intrinsic arterial stiffness in Munich Wistar Fromter rats, a genetic model of chronic kidney disease","volume":"51","author":"Gil-Ortega","year":"2020","journal-title":"Am. J. Nephrol."},{"issue":"6","key":"10.1016\/j.jchromb.2026.124975_bb0065","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.jchromb.2026.124975_bb0070","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamacardio.2023.1505","article-title":"Modifiability of composite cardiovascular risk associated with chronic kidney disease in type 2 diabetes with finerenone","volume":"8","author":"Agarwal","year":"2023","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.jchromb.2026.124975_bb0075","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.yjmcc.2018.06.008","article-title":"Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice","volume":"121","author":"Bonnard","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"2","key":"10.1016\/j.jchromb.2026.124975_bb0080","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.jchromb.2026.124975_bb0085","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40119-022-00269-3","article-title":"Cardiovascular and renal outcomes with finerenone, a selective mineralocorticoid receptor antagonist","volume":"11","author":"Palanisamy","year":"2022","journal-title":"Cardiol Ther."},{"issue":"11","key":"10.1016\/j.jchromb.2026.124975_bb0090","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1124\/dmd.118.083337","article-title":"Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro","volume":"46","author":"Gerisch","year":"2018","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"10.1016\/j.jchromb.2026.124975_bb0095","first-page":"2581","article-title":"Forced degradation studies for estimation of Finerenone by RP-HPLC method","volume":"5","author":"Murugesan","year":"2021","journal-title":"Acta Sci. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2026.124975_bb0100","series-title":"FDA guidance for industry: bioanalytical method validation US Department of Health and Human Services, Food and Drug Administration, CDER","author":"Rockville","year":"2018"},{"key":"10.1016\/j.jchromb.2026.124975_bb0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jchromb.2016.07.042","article-title":"Pharmacokinetics and bioavailability assessment of miltefosine in rats using high performance liquid chromatography tandem mass spectrometry","volume":"1031","author":"Valicherla","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"10","key":"10.1016\/j.jchromb.2026.124975_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/jms.5088","article-title":"Pharmacokinetic analysis of gatifloxacin and dexamethasone in rabbit ocular biofluid using a sensitive and selective LC-MS\/MS method","volume":"59","author":"Biswas","year":"2024","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jchromb.2026.124975_bb0115","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jpba.2018.09.031","article-title":"Elucidation of pharmacokinetics of el DNA ligase I inhibitor, S012-1332 in rats: integration of in vitro and in vivo findings","volume":"162","author":"Riyazuddin","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2026.124975_bb0120","first-page":"1130","article-title":"Development and validation of LC-MS\/MS method for quantification of el PP2A - beta-catenin signalling inhibitor, S011-2111 in mice plasma: application to its preclinical pharmacokinetic studies","author":"Riyazuddin","year":"2019","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"7","key":"10.1016\/j.jchromb.2026.124975_bb0125","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ddr.21463","article-title":"Determination of permeability, plasma protein binding, blood partitioning, pharmacokinetics and tissue distribution of withanolide a in rats: a neuroprotective steroidal lactone","volume":"79","author":"Singh","year":"2018","journal-title":"Drug Dev. Res."},{"issue":"4","key":"10.1016\/j.jchromb.2026.124975_bb0130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/ddr.21433","article-title":"Evaluation of oral pharmacokinetics, in vitro metabolism, blood partitioning and plasma protein binding of el antidiabetic agent, S009-0629 in rats","volume":"79","author":"Valicherla","year":"2018","journal-title":"Drug Dev. Res."},{"issue":"8","key":"10.1016\/j.jchromb.2026.124975_bb0135","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2174\/1389200224666230817101950","article-title":"Preclinical pharmacokinetics and CYP modulation activity of chebulinic acid: a potent molecule against metabolic disease","volume":"24","author":"Biswas","year":"2023","journal-title":"Curr. Drug Metab."},{"issue":"5","key":"10.1016\/j.jchromb.2026.124975_bb0140","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.fct.2011.01.012","article-title":"PAMPA permeability, plasma protein binding, blood partition, pharmacokinetics and metabolism of formononetin, a methoxylated isoflavone","volume":"49","author":"Singh","year":"2011","journal-title":"Food Chem. Toxicol."},{"issue":"1","key":"10.1016\/j.jchromb.2026.124975_bb0145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/10286020.2017.1396976","article-title":"The intestinal absorption properties of flavonoids in hippophae rhamnoides extracts by an in situ single-pass intestinal perfusion model","volume":"21","author":"Xin","year":"2019","journal-title":"J. Asian Nat. Prod. Res."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226000644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226000644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:59:13Z","timestamp":1776164353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023226000644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":29,"alternative-id":["S1570023226000644"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.124975","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic, tissue distribution, permeability, protein binding and stability studies of finerenone in SD rats using validated UPLC and LC-MS method","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.124975","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124975"}}